You may also experience reduced cravings, better mobility, and more energy
Caveat: the 0.6mg cap means less total weight loss for anyone needing a full dose
Over time, researchers discovered additional benefits beyond glucose management
Vedolizumab, a humanized IgG1 monoclonal antibody that specifically targets the 47 integrin heterodimer without affecting 41, represents the prototypical gut-selective anti-trafficking agent approved by FDA, EMA, and PMDA based on the GEMINI trials demonstrating superior efficacy over placebo for both induction and maintenance in moderate to severe UC (GEMINI 1: 47.1% clinical response and 16.9% remission at week 6
Thus, the presented personalized approach to the cumulative risk assessment for the development and correction of ADRs associated with an increase in the level of toxic VPA metabolites in the blood and urine allows clinicians to adapt previously known classical methods of treatment using valproate to individual patients from the standpoint of pharmacogenomics and pharmacometabolomics
